CalciMedica (NASDAQ:CALC) Issues Earnings Results

CalciMedica (NASDAQ:CALC) issued its quarterly earnings data on Tuesday. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($1.27) by $1.03, FiscalAI reports.

CalciMedica Trading Up 0.7%

NASDAQ:CALC traded up $0.01 during trading hours on Wednesday, hitting $1.38. 44,571 shares of the stock were exchanged, compared to its average volume of 174,953. The company’s 50 day moving average is $1.59 and its two-hundred day moving average is $3.37. CalciMedica has a twelve month low of $1.00 and a twelve month high of $36.00. The company has a quick ratio of 5.58, a current ratio of 5.58 and a debt-to-equity ratio of 1.67. The company has a market capitalization of $9.43 million, a P/E ratio of -0.20 and a beta of 0.84.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on CALC shares. Weiss Ratings upgraded shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. HC Wainwright restated a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. Guggenheim began coverage on CalciMedica in a report on Thursday, August 20th. They set a “buy” rating for the company. UBS Group reiterated a “neutral” rating on shares of CalciMedica in a research report on Thursday, August 13th. Finally, Wall Street Zen downgraded CalciMedica from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 12th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, CalciMedica has a consensus rating of “Hold” and an average price target of $50.00.

CalciMedica Company Profile

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses. CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being evaluated as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury.